Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Transformational results in Phase 3 ENHANCE program for COPD
NDA submission expected Q2 2023
Strong balance sheet to support planned US commercial launch
Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT
LONDON and RALEIGH, N.C., March 07, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2022, and provides a corporate update.
